Gyongyi Szabo, MD, PhD, is Professor and Vice Chair of Research in the Department of Medicine and serves as Associate Dean for Clinical and Translational Research and Director of the MD/PhD program at the University of Massachusetts Medical School. Dr. Szabo received her MD from the University Medical School of Debrecen, Hungary, and her PhD from the National Academy of Sciences, Budapest, Hungary. She completed internal medicine residency and gastroenterology fellowship training at the University of Massachusetts Medical School. As a physician scientist, she is involved in patient care and leads clinical and translational research projects in liver diseases.
Dr. Szabo's research investigates the cellular and molecular mechanisms of immunity and inflammation in the liver including alcoholic and non-alcoholic fatty liver disease and viral hepatitis infection. She had uninterrupted NIH funding since 1989 and her current support includes an NIH merit award. Her recent research focuses on the role of pattern recognition receptor signaling and inflammasome activation in alcoholic and non-alcoholic liver diseases and in alcohol-induced acceleration of hepatitis C virus infection. She currently studies dendritic cell antigen presentation and the molecular and cellular mechanisms of alcohol- and hepatitis C- induced modulation of inflammation. She is an internationally recognized leader in the field of liver immunology and has been organizer and invited speaker at numerous international and national conferences, published papers in the high-ranking journals in the field liver research. Dr. Szabo’s laboratory has been a training site for domestic and international fellows and physician scientists in the field of liver diseases and immunology.
Dr. Szabo has served AASLD in a number of roles including Chair of the Basic Research Committee and Chair of the NIH Liaison Committee, abstract review panels and the Scientific Program Committee. Dr. Szabo is Associate Editor of HEPATOLOGY and served as member of Liver Action Plan and the National Commission for Digestive Diseases for the NIDDK. She was a standing member of the NIH Hepatobiliary Study Section and participated in numerous other study sections for NIDDK, NIAID, NCAM, NIDA, and NIAAA. Dr. Szabo has received the distinction of a Doctor Honoris Causa from the Semmelweis University, Budapest, Hungary and was invited as keynote speaker at several international and national meetings. Dr. Szabo is a member of the National Advisory Board for the NIAAA, and serves as member of the Advisory Boards for the American Beverage Medical Foundation and the Alpha-1 Foundation.
Conflict of Interest
Dr. Gyongyi Szabo serves on the advisory boards for Alcohol Research and Health (NIAAA), Bile Acid Council, GALAXY Project, Nature Reviews in Gastro & Hepatology, NIH ExRNA Program, Prevent Cancer Foundation, Trek Therapeutics, University of Colorado Alcohol Center, University of Pittsburgh, MSTP EAB, University of Southern California Liver Center and Yale University Liver Center. She also serves on the editorial boards for ACER and Hepatology. Dr. Szabo receives grant and research support from Bristol-Myers Squibb, Genentech, Genfit, Gilead, Intercept, NIH-NIAAA, Takeda, Tobira, University of Florida and Vertex. She is a scientific consultant for Novartis, Orbimed, Roviant, Salix, Tobira and Verlyx.